Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4850553
Max Phase: Preclinical
Molecular Formula: C55H75F12N13O15
Molecular Weight: 930.17
Molecule Type: Unknown
Associated Items:
ID: ALA4850553
Max Phase: Preclinical
Molecular Formula: C55H75F12N13O15
Molecular Weight: 930.17
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NCCN1CCN(C(=O)CCCC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C47H71N13O7.4C2HF3O2/c1-32(43(64)56-38(14-7-8-21-48)46(67)54-33(2)61)53-45(66)37(15-10-22-52-47(49)50)51-23-26-57-27-29-59(30-28-57)41(62)18-9-11-34-19-24-58(25-20-34)31-42(63)60-39-16-5-3-12-35(39)44(65)55-36-13-4-6-17-40(36)60;4*3-2(4,5)1(6)7/h3-6,12-13,16-17,32,34,37-38,51H,7-11,14-15,18-31,48H2,1-2H3,(H,53,66)(H,55,65)(H,56,64)(H4,49,50,52)(H,54,61,67);4*(H,6,7)/t32-,37-,38-;;;;/m0..../s1
Standard InChI Key: FOYLSLPDWIFBSQ-WLYMSNLHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 930.17 | Molecular Weight (Monoisotopic): 929.5599 | AlogP: 0.95 | #Rotatable Bonds: 23 |
Polar Surface Area: 280.52 | Molecular Species: BASE | HBA: 12 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 20 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.56 | CX Basic pKa: 11.99 | CX LogP: -1.64 | CX LogD: -6.59 |
Aromatic Rings: 2 | Heavy Atoms: 67 | QED Weighted: 0.04 | Np Likeness Score: -0.40 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):